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Myocardial Viability
Dead or Alive Is Not the Question!*
Eike Nagel, MD, PHD, Andreas Schuster, MD
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aWhen talking about viability—or better: hibernat-
ing myocardium—the question is not: “dead or
alive,” the question is rather “what needs to be done
to improve the patient’s symptoms and prognosis.”
Little is known to answer this question.
The difficulties start with the definition of hiber-
nating myocardium as “a state of myocardial hypo-
contractility during chronic hypoperfusion, in the
presence of completely viable myocardium which
recovers functionally upon revascularization.” This
See page 494
definition is problematic in the clinical setting
because it is not entirely clear how we exactly define
myocardial hypocontractility, how we define hypo-
perfusion (especially given that there is perfusion
contraction matching), how we define functional
recovery, and most important for a clinical test, how
can we predict functional recovery?
The next level of complexity is the question of
what is most important for the prognosis of the
patient: left ventricular volumes and function, pres-
ence and extent of myocardial infarction, presence
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
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vascular Imaging or the American College of Cardiology.
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nd extent of myocardial ischemia, or a combina-
ion of some or all of the parameters mentioned?
There are several things we know:
1. End-diastolic volume (EDV) and ejection
fraction (EF) are strong parameters of outcome
in a large variety of patient groups (1–3).
2. The presence and extent of myocardial in-
farction are strong parameters of outcome
and seem to be superior to EDV and EF in
a large variety of patient groups (4,5).
3. The presence of large amounts of myocardial
ischemia is a strong predictor of negative
outcome (6).
However, we do not know:
1. Whether the presence of viable myocardium
is relevant to predict outcome.
2. Whether areas of peri-infarct ischemia are
relevant.
3. Whether improvement of function after re-
vascularization reduces the patient’s risk for
subsequent events.
4. Which test/parameter to use to define hiber-
nating myocardium.
The recent imaging substudy of the prospective
ulticenter outcome STICH (Surgical Treatment
or Ischemic Heart Failure) trial can be used as an
xample to highlight these difficulties (7). Hiber-
ating myocardium was assessed in 601 patients
ith ischemic cardiomyopathy (EF 35%) with
ingle-photon emission computed tomography
SPECT) or dobutamine stress echocardiography
DSE). Two hundred ninety-eight patients received
edical therapy and coronary artery bypass grafting,
nd 303 were randomized to optimal medical ther-
py alone. There was no association of hibernating
netic reson
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510myocardium and outcome in all patients and, im-
portantly, no differences in prognosis, irrespective
of whether patients with significant amounts of
hibernating myocardium were revascularized or re-
ceived medical therapy only. Considering the un-
known variables mentioned in the previous text, it is
important to note that the amount of myocardium
required to classify the patients as having significant
amounts of hibernating myocardium were different
for SPECT and DSE and more than usually used in
clinical practice. With SPECT, 65% of the myo-
cardium had to be hibernating (11 segments), and
with DSE, 31% of the myocardium (5 segments).
In addition, the study considered the presence of
hibernating tissue, irrespective of whether it was
subtended by a diseased coronary artery or not.
Furthermore, we need to acknowledge that SPECT
and DSE may not represent the optimal investiga-
tion for hibernating myocardium because they have
inherent technical limitations, such as a lower
resolution and lower sensitivity of SPECT to detect
subendocardial scarring in comparison to cardiac
magnetic resonance (CMR) (8), as well as limited
Wall Motion Abnormalities at Rest
e Presence of Coronary Artery Disease
Revascularization
larization
edical Therapy
Medical Therapy
LDDSMR
– +
LGE
– +
Transmurality
<50% >50%
Algorithm to Assess Hibernating Myocardium With CMR
ence of wall motion abnormalities at rest in segments subtended
sed coronary artery, scar imaging serves as a ﬁrst-line test. In the
f scar (likelihood of functional recovery 78% [19]) and in the
f scar with a transmurality of 50% (likelihood of functional
8% [19]), late gadolinium enhancement (LGE) is sufﬁcient to pre-
onal recovery. In the presence of scars with a transmurality of 1%
elihood of functional recovery 53% [19]), low-dose dobutamine
netic resonance (LDDSMR) testing allows for the assessment of
reserve, which guides further management. CMR  cardiac mag-
ance.endocardial border definition and acoustic windows
for DSE. The fact that different noninvasive inves-
tigations provide information on different aspects of
the pathophysiology (metabolism, scar, contractile
reserve) consequently leads to results that may
depend on the chosen imaging test (9). Indeed,
previous meta-analyses have demonstrated the fea-
sibility of noninvasive testing to guide revascular-
ization when including positron emission tomogra-
phy and CMR (10,11). Even though there is less
evidence, the importance of an additional ischemic
component to the presence of hibernating myocar-
dium in patients with ischemic cardiomyopathy is
increasingly recognized (12).
CMR has several options to characterize patients
with suspected hibernating myocardium (13). It is
the established reference standard to measure global
left ventricular volumes and function (14), and it is
optimally suited to assess regional wall thickness
and motion (15). This is further advanced by using
dobutamine stress testing and assessing quantitative
parameters such as strain, for example, with tagging
(16) or feature tracking (17). In addition, the
amount of late gadolinium enhanced (LGE) tissue
represents scar with unprecedented accuracy
(18,19). Viable tissue is then defined as dysfunc-
tional myocardium without scar.
In this issue of iJACC, Romero et al. (20) provide
a meta-analysis of the value of 3 different diagnostic
strategies with CMR to predict functional recovery
after revascularization. Hibernating tissue is defined
as a segment: 1) of end-diastolic wall thickness of
5.5 to 6 mm; 2) with a wall motion abnormality at
rest, but 50% transmurality of scar; or 3) that
demonstrates functional recruitment (contractile re-
serve) during low-dose dobutamine stress. They
also tested other cutoffs for LGE as well as a
combination of LGE with low-dose dobutamine
stress. The major findings are:
1. LGE with a cutoff value of 50% transmural-
ity yields the highest sensitivity and negative
predictive value (NPV). Using a higher or a
lower cutoff value for the definition of hiber-
nation can increase either sensitivity (with
reduced specificity) or specificity (with re-
duced sensitivity). However, the strongest
differentiation between improvement and
nonimprovement is reached with the stan-
dard cutoff used by most authors and recom-
mended in the guidelines (21).
2. Low-dose dobutamine yields the highest
overall accuracy and the best specificity andin th
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5113. End-diastolic wall thickness shows a good
sensitivity and NPV but only reasonable
PPV and poor specificity.
These results are very interesting and bring us
back to point 4 of the aforementioned unknown
variables. Which parameter to assess when looking
at hibernating myocardium? If we would like to
look at “dead” tissue with scar imaging, we reach
excellent sensitivity (95%) and NPV (90%). On the
other hand, if we would like to look at “living” tissue
with contractile reserve dobutamine testing, we
reach excellent specificity (91%) and PPV (93%). It
is therefore not surprising that a combination of
different CMR parameters—most importantly, a
nonviability test (LGE) and a viability test (inotro-
pic stimulation with dobutamine)—seem to be the
optimal combination to assess hibernating myocar-
dium (22–24). However, as pointed out by the
authors of the current paper (20), it is also important
to note that in the absence of scar or in the presence of
scar with 50% transmurality, LGE imaging alone,
eems to be sufficient without exposing the patient to2007;100:930–6.
1
1
Stunning, hibernaImportantly, this meta-analysis is conducted on
he basis of segments rather than patients and
unctional improvement rather than outcome.
hus, many of the questions in the previous text
annot be finally answered and require further
esearch.
Given the number of variables that remain un-
nown at this stage, we can only speculate about the
est diagnostic strategy. For the time being, our
ain target may remain to improve regional func-
ion by revascularization, in those patients who have
high likelihood of functional recovery, but sparing
hose with low likelihood of functional recovery
rom interventional procedures. As such, a combi-
ation of scar imaging providing information on
rreversible damage, with a functional test providing
nformation on the likelihood of functional recov-
ry, seems to be the best strategy.
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